MedWatch

Orphazyme makes changes to board of directors

Andrew Mercieca will be proposed as member of the Board of Directors at Orphazyme in April following Thursday's announcement that Catherine Moukheibir will step down from her position.

Photo: Orphazyme/PR

Orphazyme has appointed Andrew Mercieca as observer and consultant to the board, intending to formally appoint him member at the company's annual general meeting in April, it reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs